Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.59 |
| ▸ | CCR2 | P41597 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115330 | 0.85 | DRD3 (0.60) | SLC2A1MCHR1 | |
| SCHEMBL3106225 | 0.84 | SLC2A1 (0.60) | SLC2A1MCHR1CCR2 | |
| SCHEMBL3111836 | 0.83 | SMN1; SMN2 (0.55) | SLC2A1CCR2 | |
| Hydrochloric Acid SCHEMBL6712354 | 0.83 | SLC2A1 (0.59) | SLC2A1MCHR1CCR2 | |
| SCHEMBL6805196 | 0.80 | SLC2A1 (0.55) | SLC2A1MCHR1CCR2 | |
| SCHEMBL6807489 | 0.78 | SLC2A1 (0.52) | SLC2A1MCHR1CCR2 | |
| SCHEMBL3121723 | 0.76 | DRD2 (0.51) | SLC2A1MCHR1 | |
| SCHEMBL6710630 | 0.76 | CCR2 (0.53) | SLC2A1CCR2 | |
| SCHEMBL3123342 | 0.76 | SLC2A1 (0.50) | SLC2A1CCR2 | |
| SCHEMBL3117184 | 0.75 | DRD2 (0.54) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| US-9023656-B2 | Reactive mass labels | ELECTROPHORETICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-1907860-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100178710-A1 | Mass Labels | ELECTROPHORETICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| EP-1907860-A2 | MASS LABELS | Electrophoretics Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012849-A2 | MASS LABELS FOR BIOMOLECULES CONTAINING A 2,6-DIMETHYL-PIPERIDIN-l-YL METHYLENE OR A PYRIMIDIN-2-YL THIOMETHYLENE MASS MARKER MOIETY AND A SUCCINIMID-OXY-CARBONYL REACTIVE FUNCTIONAL GROUP | ELECTROPHORETICS LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1351935-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178710-A1 | Mass Labels | B2M, SRRM2, CCNB1 | SLC2A1 3324/4885MCHR1 429/4885CCR2 73/4885 |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC2A1 345/4885MCHR1 339/4885CCR2 228/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | SLC2A1 419/4885MCHR1 547/4885CCR2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.